Satoshi Muraoka

Satoshi Muraoka

Auto-generated profile, based on publicly available information

Satoshi Muraoka

Laboratory of Proteomics for Drug Discovery, Center for Drug Design Research, National Institute of Biomedical Innovation, Health and Nutrition, Osaka, Japan; and

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2022 in ACS Omega
Verified
Journal Article
Open access
SMSatoshi Muraoka
Satoshi Muraoka
MHMasayo Hirano
Masayo Hirano
JIJunko Isoyama
Junko Isoyama
MIMimiko Ishida
Mimiko Ishida
TTTakeshi Tomonaga
Takeshi Tomonaga
JAJun Adachi
Jun Adachi
Extracellular vesicles (EVs) are ubiquitously secreted by almost every cell type and are present in all body fluids. Blood-derived EVs can be used as a promising source for biomarker monitoring in disease. EV proteomics is currently being analyzed in clinical specimens. However, their EV proteomics preparation methods are limited in throughput for human subjects. Here, we introduced a novel automated EV isolation and sample preparation method using a magnetic particle processing robot for automated 96-well processing of magnetic particles for EV proteomics analysis that can be started with a low volume of multiple clinical samples. The automation of EV purification reduced the coefficient of variation of protein quantification from 3.5 to 2.2% compared with manual purification, enabling the quantification of 1120 proteins in 1 h of MS analysis. This automated proteomics EV sample preparation is attractive for processing large cohort samples for biomarker development, validation, and routine testing.

17 May 2023 in Molecular Omics
Verified
Journal Article
Closed access
PDF file
DGDaigo Gunji
Daigo Gunji
RNRyohei Narumi
Ryohei Narumi
SMSatoshi Muraoka
Satoshi Muraoka
JIJunko Isoyama
Junko Isoyama
NINarumi Ikemoto
Narumi Ikemoto
JAJun Adachi
Jun Adachi
Colorectal cancer (CRC), a common malignant tumour of the gastrointestinal tract, is a life-threatening cancer worldwide. Mutations in KRAS and BRAF, the major driver mutation subtypes in CRC, activate the RAS pathway, contribute to tumorigenesis in CRC and are being investigated as potential therapeutic targets. Despite recent advances in clinical trials targeting KRASG12C or RAS downstream signalling molecules for KRAS-mutant CRC, there is a lack of effective therapeutic interventions. Therefore, understanding the unique molecular characteristics of KRAS-mutant CRC is essential for identifying molecular targets and developing novel therapeutic interventions. We obtained in-depth proteomics and phosphoproteomics quantitative data for over 7900 proteins and 38 700 phosphorylation sites in cells from 35 CRC cell lines and performed informatic analyses, including proteomics-based coexpression analysis and correlation analysis between phosphoproteomics data and cancer dependency scores of the corresponding phosphoproteins. Our results revealed novel dysregulated protein–protein associations enriched specifically in KRAS-mutant cells. Our phosphoproteomics analysis revealed activation of EPHA2 kinase and downstream tight junction signalling in KRAS-mutant cells. Furthermore, the results implicate the phosphorylation site Y378 in the tight junction protein PARD3 as a cancer vulnerability in KRAS-mutant cells. Together, our large-scale phosphoproteomics and proteomics data across 35 steady-state CRC cell lines represent a valuable resource for understanding the molecular characteristics of oncogenic mutations. Our approach to predicting cancer dependency from phosphoproteomics data identified the EPHA2-PARD3 axis as a cancer vulnerability in KRAS-mutant CRC.

8 December 2021 in Frontiers in Microbiology
Verified
Journal Article
Open access
Kazusato OhshimaKazusato Ohshima
Kazusato Ohshima
SKShusuke Kawakubo
Shusuke Kawakubo
SMSatoshi Muraoka
Satoshi Muraoka
FGFangluan Gao
Fangluan Gao
KIKanji Ishimaru
Kanji Ishimaru
SFShinji Fukuda
Shinji Fukuda
Scallion mosaic virus (ScaMV) belongs to the turnip mosaic virus phylogenetic group of potyvirus and is known to infect domestic scallion plants (Allium chinense) in China and wild Japanese garlic (Allium macrostemon Bunge) in Japan. Wild Japanese garlic plants showing asymptomatic leaves were collected from different sites in Japan during 2012–2015. We found that 73 wild Japanese garlic plants out of 277 collected plants were infected with ScaMV, identified by partial genomic nucleotide sequences of the amplified RT-PCR products using potyvirus-specific primer pairs. Sixty-three ScaMV isolates were then chosen, and those full genomic sequences were determined. We carried out evolutionary analyses of the complete polyprotein-coding sequences and four non-recombinogenic regions of partial genomic sequences. We found that 80% of ScaMV samples have recombination-like genome structure and identified 12 recombination-type patterns in the genomes of the Japanese ScaMV isolates. Furthermore, we found two non-recombinant-type patterns in the Japanese population. Because the wild plants and weeds may often serve as reservoirs of viruses, it is important to study providing the exploratory investigation before emergence in the domestic plants. This is possibly the first epidemiological and evolutionary study of a virus from asymptomatic wild plants.

1 September 2025 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
NINaotoshi Iwahara
Naotoshi Iwahara
SMSatoshi Muraoka
Satoshi Muraoka
TSTaro Saito
Taro Saito
MHMasayo Hirano
Masayo Hirano
KYKazuki Yokokawa
Kazuki Yokokawa
SHShin Hisahara
Shin Hisahara
Extracellular vesicles (EVs) are membrane-bound particles that are released into the extracellular space and are believed to play a role in the pathogenesis of neuroinflammation and neurodegeneration. Nevertheless, the precise role of these vesicles in the context of multiple sclerosis (MS) remains uncertain. The objective of this study was to identify the distinctive characteristics of EVs associated with MS. EVs were isolated from CSF using phosphatidylserine affinity methods. Mass spectrometry was used to analyze CSF samples and EVs isolated from those CSF samples collected from a discovery cohort of 10 patients with other neurologic diseases (ONDs) and 10 patients with MS. In addition, mass spectrometry was used to analyze EVs isolated from CSF samples in a validation cohort of 24 patients with ONDs, 38 patients with MS, and 14 patients with neuromyelitis optica spectrum disorders. The results revealed notable increases in the levels of 33 proteins in the CSF samples and 100 proteins in the CSF-derived EVs from patients with MS in the validation cohort. Increases in the levels of ITGA4, ITGAX (CD11c), MS4A1 (CD20), CD3E, CD4, and CD8A, which are marker proteins of lymphocytes and myeloid cells, including activated microglia and dendritic cells, were observed in the CSF-derived EVs in the discovery cohort. The results of the validation cohort revealed that the levels of 4 proteins, ITGA4, ITGAX, MS4A1, and CD3E, were significantly greater in patients with MS than in patients with ONDs. Furthermore, the level of ITGAX was greater in the patients with confirmed disability worsening (CDW) than in those without CDW. The results of the receiver operating characteristic (ROC) and Kaplan-Meier analyses indicated that ITGAX levels in CSF-derived EVs may prove useful in predicting disease prognosis. Our findings suggest that CSF-derived EVs reflect immunologic changes in MS and other neuroimmune diseases. In addition, these results raise the possibility that changing in myeloid cells and lymphocytes may also play a role in the pathogenesis of MS. CSF-derived EVs may serve as indicators of MS disease severity and could be used as biomarkers in the future.